Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer

PURPOSE: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small molecule ALK inhibitor. Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those that do respond. This study aimed to define...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Doebele, Robert C., Pilling, Amanda B., Aisner, Dara L., Kutateladze, Tatiana G., Le, Anh T., Weickhardt, Andrew J., Kondo, Kimi L., Linderman, Derek, Heasley, Lynn E., Franklin, Wilbur A., Varella-Garcia, Marileila, Camidge, D. Ross
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3311875/
https://ncbi.nlm.nih.gov/pubmed/22235099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2906
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars